Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2012

View Archived Issues

Collaborating companies design novel anticancer agents

U.S. study links SNPs to aggressive prostate cancer and associated mortality

Novel PPAR-gamma agonist tested in polycystic kidney disease model

RDX-5791 studied for effects on sodium excretion in healthy volunteers

ChemoCentryx compound shows efficacy in diabetic nephropathy model

Novel therapeutic indolizine derivatives developed

Incyte researchers prepare new JAK inhibitors

New CDK9 inhibitors presented by Novartis

Heptares Therapeutics patents new adenosine A2A receptor antagonists

Sanofi divulges new chlamydia vaccines

Ambrx and Merck & Co. to design optimized biologic-drug conjugates

KineMed enters collaboration with GSK

Bionomics and Merck Serono terminate agreement

Scientists at Roche report novel tyrosine-protein kinase inhibitors

Transition Therapeutics reports on TT-401 study

Genta reaches agreement on phase III tesetaxel trial

Ongoing congress features data from first PD trial assessing exenatide efficacy/safety/tolerability

FDA responds to Cellceutix pre-IND submission

Zealand Pharma announces new partnership

Forma Therapeutics and TD2 launch new collaboration

Enrollment complete in phase II/III trial of Huntington's disease drug candidate

Promising first-in-human daratumumab results presented at recent meetings

Innate Immunotherapeutics reports interim data from MIS-416 trial

Infinity Pharmaceuticals halts saridegib trials

UCB and Harvard University expand research alliance

EMA to conduct centralized review of elvitegravir MAA

Pfizer receives FDA complete response letter for tafamidis NDA

Orexo completes dose proportionality study of opioid dependence drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...